Get started
Author

Jürgen August Alt

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial
2019 · Luis Paz-Ares, Mikhail Dvorkin, et al. · The Lancet · 2,281
Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial
2020 · Jonathan W Goldman, Mikhail Dvorkin, et al. · The Lancet Oncology · 688
Phase Ib evaluation of a self-adjuvanted protamine formulated mRNA-based active cancer immunotherapy, BI1361849 (CV9202), combined with local radiation treatment in patients with stage IV non-small cell lung cancer
2019 · Alexandros Papachristofilou, Madeleine M. Hipp, et al. · Journal for ImmunoTherapy of Cancer · 227
PDF
SAPPHIRE: phase III study of sitravatinib plus nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
2023 · H. Borghaei, F. de Marinis, et al. · Annals of Oncology · 103
PDF
KRAS G12C-mutated advanced non-small cell lung cancer: A real-world cohort from the German prospective, observational, nation-wide CRISP Registry (AIO-TRK-0315)
2021 · Martin Sebastian, Wilfried E.E. Eberhardt, et al. · Lung Cancer · 81
PDF
Durvalumab after definitive chemoradiotherapy in locally advanced unresectable non-small cell lung cancer (NSCLC): Real-world data on survival and safety from the German expanded-access program (EAP)
2020 · Martin Faehling, Christian Schumann, et al. · Lung Cancer · 78
Lorlatinib in pretreated ALK- or ROS1-positive lung cancer and impact of TP53 co-mutations: results from the German early access program
2021 · Nikolaj Frost, Petros Christopoulos, et al. · Therapeutic Advances in Medical Oncology · 49
PDF
Sotorasib in KRAS G12C-mutated non-small cell lung cancer: A multicenter real-world experience from the compassionate use program in Germany
2024 · Jan A. Stratmann, Friederike C. Althoff, et al. · European Journal of Cancer · 44
PDF
Small cell transformation in EGFR-mutated non-small cell lung cancer: DLL3 expression and efficacy of immune checkpoint inhibitors or tyrosine kinase inhibitors combined with chemotherapy
2024 · Felix Carl Saalfeld, Johanna Möller, et al. · European Journal of Cancer · 35
PDF
Clinical predictors of survival in patients with relapsed/refractory small-cell lung cancer treated with checkpoint inhibitors: a German multicentric real-world analysis
2022 · Jan A. Stratmann, Radha Timalsina, et al. · Therapeutic Advances in Medical Oncology · 24
PDF
“That was a tip from my physician”—Gender‐specific pathways of patients and relatives to outpatient psychosocial cancer counselling centres—A qualitative study
2022 · Fabian Billaudelle, Oliver Bayer, et al. · Psycho-Oncology · 13
PDF
Alemtuzumab Combined with Dexamethasone, Followed By Alemtuzumab Maintenance or Allo-SCT in “ultra High-risk” CLL: Final Results from the CLL2O Phase II Study
2014 · Stephan Stilgenbauer, Florence Cymbalista, et al. · Blood · 13
Tolerability and efficacy of the cancer vaccine UV1 in patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma planned for first-line treatment with pembrolizumab – the randomized phase 2 FOCUS trial
2024 · Anna Brandt, Christoph Schultheiss, et al. · Frontiers in Oncology · 11
PDF
Efficacy and safety analysis of the German expanded access program of osimertinib in patients with advanced, T790M-positive non-small cell lung cancer
2018 · Jan A. Stratmann, Sebastian Michels, et al. · Journal of Cancer Research and Clinical Oncology · 11
1486 Preliminary results from LuCa-MERIT-1, a phase I trial evaluating BNT116, a fixed antigen mRNA vaccine, plus cemiplimab in advanced non-small cell lung cancer after progression on PD-1 inhibition
2024 · Akin Atmaca, Jürgen Alt, et al. · 9
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients With HER2-Mutant NSCLC Across Treatment Lines: Evidence From the TRACER/HERTras Real-World Cohort
2026 · Oliver Illini, Anna-Carina Hund, et al. · Journal of Thoracic Oncology · 7
PDF
UV1 vaccination in pembrolizumab-treated patients with recurrent or metastatic head and neck cancer: A randomized multicenter phase 2 trial
2025 · Anna Brandt, Konrad Klinghammer, et al. · Med · 7
Checkpoint Inhibitor Monotherapy in Potentially Trial-Eligible or Trial-Ineligible Patients With Metastatic NSCLC in the German Prospective CRISP Registry Real-World Cohort (AIO-TRK-0315)
2023 · Frank Griesinger, Wilfried E.E. Eberhardt, et al. · JTO Clinical and Research Reports · 4
PDF
Multi-center observational study on the adherence, quality of life, and adverse events in lung cancer patients treated with tyrosine kinase inhibitors
2020 · Jelena Rosentreter, Jürgen Alt, et al. · Journal of Oncology Pharmacy Practice · 4
PDF
Durvalumab after definitive chemoradiotherapy in locally advanced NSCLC: Data of the German EAP
2020 · Martin Faehling, Christian Schumann, et al. · Data in Brief · 3
PDF
Richtig argumentieren
2000 · Jürgen August Alt · C.H.Beck eBooks · 3
PD1-1-1 Phase Ib study of BI 836880 (VEGF/Ang2 nanobody®) plus ezabenlimab (BI 754091, anti-PD-1 antibody) in patients with solid tumors
2021 · Nicolas Girard, Martin Wermke, et al. · Annals of Oncology · 2
PDF
UV1 cancer vaccine in pembrolizumab-treated patients with recurrent or metastatic PD-L1 positive head and neck squamous cell carcinoma: results from the randomized phase 2 FOCUS trial
2024 · Anna Brandt, Konrad Klinghammer, et al. · medRxiv · 1
PDF
P3.02c-091 Final Phase Ib Results of RNActive® Cancer Vaccine BI 1361849 and Local Radiation as Maintenance Therapy for Stage IV NSCLC
2017 · Alexandros Papachristofilou, Martin Sebastian, et al. · Journal of Thoracic Oncology · 1
Systemic and Intracranial Efficacy and Safety of Trastuzumab Deruxtecan in Patients with HER2-Mutant Non-Small Cell Lung Cancer across Treatment Lines: Evidence from the TRACER/HERTras Real-World Cohort.
2026 · Illini, Oliver, Hund, Anna-Carina, et al. · Open Access CRIS of the University of Bern
Works count: 52
Citation count: 3,696
H-index: 12
I10-index: 14
Year
Topic
Type